BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8223799)

  • 21. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty.
    Tung YC; Lee JS; Tsai WY; Hsiao PH
    J Formos Med Assoc; 2007 Oct; 106(10):826-31. PubMed ID: 17964961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy.
    Pescovitz OH; Comite F; Hench K; Barnes K; McNemar A; Foster C; Kenigsberg D; Loriaux DL; Cutler GB
    J Pediatr; 1986 Jan; 108(1):47-54. PubMed ID: 3080571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone mineral density and body composition in girls with idiopathic central precocious puberty before and after treatment with a gonadotropin-releasing hormone agonist.
    Alessandri SB; Pereira Fde A; Villela RA; Antonini SR; Elias PC; Martinelli CE; Castro Md; Moreira AC; Paula FJ
    Clinics (Sao Paulo); 2012; 67(6):591-6. PubMed ID: 22760897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive factors for the effect of gonadotrophin releasing hormone analogue therapy on the height of girls with idiopathic central precocious puberty.
    Brauner R; Malandry F; Rappaport R
    Eur J Pediatr; 1992 Oct; 151(10):728-30. PubMed ID: 1425790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.
    Nunez SB; Calis K; Cutler GB; Jones J; Feuillan PP
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5730-3. PubMed ID: 14671160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
    Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL
    J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone mineral density during treatment of central precocious puberty.
    Neely EK; Bachrach LK; Hintz RL; Habiby RL; Slemenda CW; Feezle L; Pescovitz OH
    J Pediatr; 1995 Nov; 127(5):819-22. PubMed ID: 7472845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
    Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A
    Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone release hormone (D-Tryp6-GnRH) in monthly injections. Its possible use in normal puberty.
    Marcondes JA; Abujamra AC; Minanni SL; Mendonca BB; Nery M; Lerario AC; Pereira MA; Abelin N; Wajchenberg BL
    Horm Metab Res; 1993 Feb; 25(2):105-9. PubMed ID: 8458605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum inhibin A and inhibin B in central precocious puberty before and during treatment with GnRH agonists.
    Sehested A; Andersson AM; Müller J; Skakkebaek NE
    Horm Res; 2000; 54(2):84-91. PubMed ID: 11251372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.
    Martínez-Aguayo A; Hernández MI; Beas F; Iñiguez G; Avila A; Sovino H; Bravo E; Cassorla F
    J Pediatr Endocrinol Metab; 2006 Aug; 19(8):963-70. PubMed ID: 16995580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy.
    van der Sluis IM; Boot AM; Krenning EP; Drop SL; de Muinck Keizer-Schrama SM
    J Clin Endocrinol Metab; 2002 Feb; 87(2):506-12. PubMed ID: 11836277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central precocious puberty in girls: internal genitalia before, during, and after treatment with long-acting gonadotropin-releasing hormone analogues.
    Jensen AM; Brocks V; Holm K; Laursen EM; Müller J
    J Pediatr; 1998 Jan; 132(1):105-8. PubMed ID: 9470009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty.
    Mansfield MJ; Rudlin CR; Crigler JF; Karol KA; Crawford JD; Boepple PA; Crowley WF
    J Clin Endocrinol Metab; 1988 Jan; 66(1):3-9. PubMed ID: 2961786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growth velocity and serum aminoterminal propeptide of type III procollagen in precocious puberty during gonadotropin-releasing hormone analogue treatment.
    Saggese G; Bertelloni S; Baroncelli GI; Di Nero G; Battini R
    Acta Paediatr; 1993 Mar; 82(3):261-6. PubMed ID: 8495081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
    Liang Y; Wei H; Zhang JL; Hou L; Luo XP
    Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs.
    Brito VN; Latronico AC; Cukier P; Teles MG; Silveira LF; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2662-9. PubMed ID: 18460564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine.
    Roth CL; Brendel L; Rückert C; Hartmann K
    Horm Res; 2005; 63(5):257-62. PubMed ID: 15995342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. D-TRP5-analogue of luteinising hormone releasing hormone in combination with cyproterone acetate to treat precocious puberty.
    Laron Z; Kauli R; Zeev ZB; Comaru-Schally AM; Schally AV
    Lancet; 1981 Oct; 2(8253):955-6. PubMed ID: 6117727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.